DOI QR코드

DOI QR Code

Agranulocytosis Induced by Ethambutol in a Patient with Pulmonary Tuberculosis

  • Moon, Kyoung Min (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Han, Min Soo (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Chung, So Hee (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Kim, Ju Ri (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Kim, Jin Young (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Jung, Sun Young (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine) ;
  • Cho, Yongseon (Division of Pulmonology, Department of Internal Medicine, Eulji University School of Medicine)
  • Received : 2014.08.17
  • Accepted : 2014.12.10
  • Published : 2015.02.28

Abstract

We report a case of agranulocytosis caused by ethambutol in a 79-year-old man with pulmonary tuberculosis. He was referred for fever and skin rash developed on 21th day after antituberculosis drugs (isoniazid, rifampicin, ethambutol, and pyrazinamide) intake. Complete blood count at the time of diagnosis of pulmonary tuberculosis was normal. On the seventh admission day, agranulocytosis was developed with absolute neutrophil count of $70/{\mu}L$. We discontinued all antituberculosis drugs, and then treated with granulocyte colony-stimulating factor. Three days later, the number of white blood cell returned to normal. We administered isoniazid, pyrazinamide, and ethambutol in order with an interval. However, fever and skin rash developed again when adding ethambutol, so we discontinued ethambutol. After these symptoms disappeared, we added rifampicin and ethambutol in order with an interval. However after administering ethambutol, neutropenia developed, so we discontinued ethambutol again. He was cured with isoniazid, rifampicin, and pyrazinamide for 9 months.

Keywords

References

  1. Umeki S. Adverse effects of antitubercular drugs and significance of measurement of the drug-stimulating lymphocyte transformation rate. Jpn J Med 1989;28:335-40. https://doi.org/10.2169/internalmedicine1962.28.335
  2. Shishido Y, Nagayama N, Masuda K, Baba M, Tamura A, Nagai H, et al. Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP): a report of four cases and review of the literature. Kekkaku 2003;78:683-9.
  3. Citron KM. Ethambutol: a review with special reference to ocular toxicity. Tubercle 1969;50:Suppl:32-6.
  4. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982;23:56-74. https://doi.org/10.2165/00003495-198223010-00003
  5. Wong CF, Yew WW. Ethambutol-induced neutropenia and eosinophilia. Chest 1994;106:1638-9.
  6. Tattersall PE. Agranulocytosis and anaemia associated with disseminated tuberculosis. Br Med J 1957;2:1351-2. https://doi.org/10.1136/bmj.2.5057.1351
  7. Jenkins PF, Williams TD, Campbell IA. Neutropenia with each standard antituberculosis drug in the same patient. Br Med J 1980;280:1069-70. https://doi.org/10.1136/bmj.280.6221.1069

Cited by

  1. Ethambutol : Agranulocytosis in an elderly patient: case report vol.1556, pp.1, 2015, https://doi.org/10.1007/s40278-015-2596-0
  2. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art vol.9, pp.7, 2021, https://doi.org/10.3390/microorganisms9071477